Barclays PLC Purchases 110,535 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Barclays PLC lifted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 143.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 187,629 shares of the company's stock after buying an additional 110,535 shares during the period. Barclays PLC owned about 0.22% of Syndax Pharmaceuticals worth $3,612,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. State Street Corp increased its holdings in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company's stock worth $72,588,000 after purchasing an additional 148,491 shares in the last quarter. Sofinnova Investments Inc. grew its holdings in shares of Syndax Pharmaceuticals by 33.9% during the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company's stock worth $44,215,000 after purchasing an additional 545,129 shares during the last quarter. First Turn Management LLC increased its stake in shares of Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company's stock valued at $22,853,000 after buying an additional 546,776 shares during the period. Millennium Management LLC raised its holdings in Syndax Pharmaceuticals by 56.3% in the 2nd quarter. Millennium Management LLC now owns 1,065,508 shares of the company's stock valued at $21,875,000 after buying an additional 383,634 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its position in Syndax Pharmaceuticals by 25.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company's stock worth $19,921,000 after buying an additional 212,799 shares during the period.

Analysts Set New Price Targets

Several brokerages have issued reports on SNDX. UBS Group started coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a "buy" rating and a $37.00 price target for the company. StockNews.com downgraded Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, November 23rd. The Goldman Sachs Group raised their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an "overweight" rating in a research report on Thursday, November 21st. Finally, HC Wainwright restated a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $36.90.

Syndax Pharmaceuticals Trading Up 1.8 %

NASDAQ SNDX traded up $0.23 during trading hours on Monday, hitting $13.31. 5,803,170 shares of the company's stock were exchanged, compared to its average volume of 1,272,546. Syndax Pharmaceuticals, Inc. has a 1-year low of $12.75 and a 1-year high of $25.34. The stock has a 50-day simple moving average of $17.17 and a 200 day simple moving average of $19.21. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -3.67 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the prior year, the firm earned ($0.73) EPS. On average, sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).